Neurocrine Biosciences (NBIX) FCF Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly FCF Margin of 13.41% for Q2 2026, up 39.0% year-over-year from 9.65% in Q2 2025, and down 20.1% on a QoQ basis from 16.78% in Q1 2026.
Neurocrine Biosciences (NBIX) FCF Margin (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported FCF Margin for 16 years, with the latest figure at 13.41% in Q2 2026.
- FCF Margin for Q2 2026 came in at 13.41%, up 39.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 25.8% (up 473.0% YoY), and the FY2025 annual result was 26.17%, up 252.0% from the prior year.
- FCF Margin eased to 13.41% in Q2 2026, from 16.78% in the prior quarter.
- Over five years, FCF Margin peaked at 646.5% in Q2 2022 and troughed at 31.8% in Q1 2023.
- A 5-year average of 54.63% and a median of 23.6% in 2024 frame the typical range for FCF Margin.
- The widest annual swing landed in 2022, when FCF Margin jumped 61227 bps; it then slumped 60833 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 34.27% in 2022, then plunged by 33 bps to 22.92% in 2023, then surged by 63 bps to 37.47% in 2024, then climbed by 29 bps to 48.52% in 2025, then sank by 72 bps to 13.41% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 13.41% in Q2 2026, 16.78% in Q1 2026, and 48.52% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.60 Bn | 42.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.44 Bn | 29.76 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.71 Bn | 17.82 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 12.03 Bn | 11.50 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | - |
| 10 | Alkermes | 8.23 Bn | 7.57 Bn | 397.90 Mn | 27.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.41% |
| Mar 31, 2026 | 17.73% |
| Dec 31, 2025 | 48.52% |
| Sep 30, 2025 | 24.28% |
| Jun 30, 2025 | 16.12% |
| Mar 31, 2025 | 9.45% |
| Dec 31, 2024 | 32.67% |
| Sep 30, 2024 | 25.80% |
| Jun 30, 2024 | 12.28% |
| Mar 31, 2024 | 23.11% |
| Dec 31, 2023 | 23.66% |
| Sep 30, 2023 | 42.48% |
| Jun 30, 2023 | 39.63% |
| Mar 31, 2023 | -29.92% |
| Dec 31, 2022 | 38.11% |
| Sep 30, 2022 | 21.91% |
| Jun 30, 2022 | 700.00% |
| Mar 31, 2022 | -13.94% |
| Dec 31, 2021 | -1.51% |
| Sep 30, 2021 | 16.72% |